by The Promise of an Ebola Vaccine
The Search for a Vaccine
Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is a severe, often fatal illness in humans. The virus is transmitted through direct contact with bodily fluids like blood or secretions of infected people or contact with contaminated surfaces and materials. Since the first confirmed cases in 1976, outbreaks have predominantly been confined to remote villages in Central and West Africa, near rainforests. However, the 2014-2016 West Africa outbreak caused over 28,000 cases and 11,000 deaths, spread over multiple countries including some major cities. This highlighted the need for accelerated vaccine development to prevent future outbreaks.
Research into an Ebola vaccine picked up pace after the 2014 outbreak. Multiple candidates were tested rapidly in clinical trials across affected regions. Among the leading candidates was rVSV-ZEBOV, developed by Merck. It uses an engineered vesicular stomatitis virus (VSV) to deliver the Zaire Ebola virus glycoprotein. Early trials showed it provided nearly 100% protection against the virus. The ring vaccination trial method was used effectively during the outbreak to test candidates. This involves vaccinating contacts of confirmed cases and their close contacts to create a immune “ring” to halt transmission.
The swift testing of candidates helped identify rVSV-ZEBOV as the most promising vaccine. In December 2019, it received regulatory approval in Europe and prequalification from the World Health Organization (WHO). This was a huge step forward in preparing for future outbreaks. The vaccine’s effectiveness, availability and WHO prequalification designation means global health authorities now have an approved tool to fight new outbreaks. Multiple manufacturing sites around the world also help ensure adequate supply.
Challenges of Developing an Ebola Vaccine
Developing any new vaccine against a viral disease comes with big challenges. Ebola posed additional difficulties due to its lethality, lack of prior exposure in humans and constraints of testing candidates during outbreaks in remote areas with poor infrastructure and healthcare systems. Some of the key challenges overcome included:
– Isolating and characterizing the Ebola virus: Its discovery in 1976 was followed by decades of research to understand its pathophysiology, mutations and relationship to other filoviruses like Marburg. This basic virology underpins vaccine design.
– Finding suitable vaccine platforms: VSV, adenovirus and other vector-based platforms able to induce durable immunity were explored. VSV-vectored vaccines proved most effective in trials.
– Conducting efficacy trials in outbreak settings: Traditional Phase 3 trials weren’t feasible during outbreaks. Ring vaccination and ‘Ebola ça Suffit’ trials established proof-of-concept for candidates in real-world conditions with strong public trust and engagement.
– Ensuring cGMP manufacture at scale: Early candidates were made in research labs but scaling up to clinical and commercial levels required massive investments to satisfy global regulatory standards for quality and safety.
– Addressing cold chain challenges in remote areas: The vaccines require freezing temperatures for stability, posing logistical issues for delivery to villages without reliable electricity. Novel formulations and packaging aim to overcome this.
– Building and maintaining public trust: Communities affected by Ebola were wary and trials required extensive community outreach to gain informed consent. Maintaining trust even during the crisis was critical for trial success and future outbreak response.
– Sustaining funding over decades: Developing the first fully validated Ebola vaccines took over 40 years of stop-start work amid outbreaks. Committed long term funding was vital to reach this milestone.
Surmounting these hurdles through collaborative global efforts laid the groundwork for the approved vaccine today for emergency stockpiling and outbreak response. However, continued research aims to cover all Ebola virus strains and improve formulations even further.
Expanding Vaccine Coverage
While the rVSV-ZEBOV vaccine is a major breakthrough, work remains to refine existing options and develop next-generation vaccines. Key ongoing research areas include:
– Multi-strain coverage: Current vaccines target only the Zaire species, but two other species – Sudan and Bundibugyo – can also cause disease. New candidates aim to provide pan-filovirus protection.
– Thermostability: Heat-stability formulations avoiding the cold chain could enhance access in remote areas lacking infrastructure during outbreaks.
– Single-dose protection: Whether immunity from a single dose can confer immediate protection, versus the current two-dose schedule extending over one month.
– Long-term immunity: Duration of protective antibody levels post-vaccination to determine booster needs, and development of T-cell mediated immune memory.
– Alternative platforms: Other delivery methods like protein sub-unit or nucleic-acid platforms with good safety profiles are also in development.
– Mucosal immunity: Targeting mucosal surfaces like inside the nose where the virus enters could add an important layer of protection against infection.
– Pediatric vaccines: Ensuring suitable formulations and dosing for infants and children who are also at risk.
Continued progress will strengthen the vaccine arsenal, help achieve WHO prequalification of additional candidates, and ensure a sustainable, modern toolkit against this deadly pathogen. With ongoing research, the goal of developing a “one-shot, keep-it-in-the-fridge” Ebola vaccine may be within reach sooner than imagined.
The development of an approved Ebola vaccine has been a remarkable scientific and global health achievement overcoming immense challenges. With accelerated progress in the past decade, we now have a validated vaccine that can help break chains of outbreak transmission when deployed rapidly. Post-licensure research aims to further optimize the vaccine based on real-world experience and extend coverage to all virus strains. Continued international cooperation will be vital to conduct efficacy trials efficiently, ensure adequate supply stockpiles globally, and empower local health workers for swift outbreak response. There remains work to be done, but the tools are now in place to curb future Ebola epidemics with a powerful new vaccine. After four decades, this milestone brings us closer to ultimately taming this terrifying disease.
Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
